Usal and IBSAL participates in the National Megaproceen project to treat spinal wardrobe with artificial intelligence

A blood diseases specialist in the University Assistance Complex in Salasa, Professor of Medicine at the University of Salamanca and researcher at the Institute of Biomedical Research in Salama (IBSAL), Maria Dies Camello, is the coordinator of national umbrellas, SMD in Spain, integrating genetic medicine designated in the public health system and integrating enlightened results by patients.

This comprehensive and multidisciplinary tool, which will be developed in 2025 and 2026 in a project led by Castilla Y León, Causa and Ibsal, will share 25 hospitals and research centers of 16 independent society thanks to the general financing that is granted by approximately 3.4 million people granted by the Carlos III Health Institute, and they turn into Myeloid Research and Sevent My. Solutions in their battle against the disease.

This project is in line with the representation in personal medicine, the Ministry of Health, Castilla Y León, in an attempt to provide individualism for the strategy of diagnosis, treatment and care in all patients, in this study, applied to the diseases of the melawid.

The importance of this study decreases, according to Díez Campelo, in which we face an orphan disease that is still a lot of research to go forward, with a difficult diagnosis, very heterogeneous and with a few effective treatments, and for the tools required after that, it is not completely implanted in a hospital service portfolio, such as mass sequence. “

Skopped marrow syndromes, which are considered a type of cancer, are changes that can occur when blood -producing cells in the bone marrow become abnormal cells, and this leads to lowering white, red blood cells or platelets. Although the incorporation of genetic studies has allowed some progress in understanding this heterogeneous group of sophisticated blood tumors, challenges are still presented in terms of diagnosis, vapor class and effective treatment. In addition, it affects the particularly weak population, given that most currently active cases in Spain (about 2000 new every year) are compatible with people over 70 years old, and they are no longer candidates for planting and have few treatment options.

In this scenario, already in 2017, with the financing of the first FIS coordinator project, according to the head of Spanish iconic cordial syndromes (GESMD), the network began to appoint a network to enhance the personal diagnosis of patients. In 2020, the second coordinated project, umbrella, which will also arrive under Díez Campelo format, seeks to “umbrellas and provide all professionals to the new generation sequence to improve the vow of patients, especially in the centers where these technologies are not found.” More than 500 patients were included in the project between 2021 and 2023, while new hospitals were launched, and in 2023, the third coordinated project was launched, umbrella-Somah, with the target, specifically, to continue to “add more centers and ensure more and more patients benefit from this progress.”

Now, with the rules that have already created to develop a coordinated strategy that integrates clinical, genetic and molecular data for SMDS in the Spanish registry (ResMD), this new project “is the peak to create a tool that allows all blood doctors to apply dedicated medicine for patients with sigad in Spain.”

Patient experiences

To do this, you suggest umbrella shading-as you improve the integration of registration data, including YY conception on the perception and experience that users reported during the care process, and the creation of the central biobanco for future studies.

“We have to understand what the needs of each patient to adapt and improve the quality of his life, because the only recovery treatment is implantation and almost all of them are diagnosed in ages that are no longer cultivated. On the one hand, we have a group of patients with low risk, who have a long survival, but the quality of life is very poor, because they depend on blood transfusion, and on the other hand, patients who need active treatment to survive; But in both cases, it is important to measure your experience and define it to customize the treatment. “

Likewise, artificial intelligence models (AI) are presented as promising tools for SMDS, allowing the analysis of large data sizes and the identification of complex patterns of personal treatments. In addition, procedures will be launched to improve patient diagnosis, including verification of new tools such as the optical mapping of genome (OGM), bone marrow images and progress in predictive strategies and formation in patients with special attention SMD, including patients with TP53 mutation, nibasia related to treatment with patients with bacterial bacterial periods.

However, the development of this project will include significant progress in the approach of shed syndrome, which will not only benefit from patients but also for the entire health system, when improving treatments, reducing the costs and toxicity of inappropriate medicines, and improving the response to response that combines all of this with the patient’s satisfaction.